510(k) Report

510(k) · Cleared

Recalled · Class II · 2024

DRG SLV Testosterone Elisa Test

K052649510(k) TraditionalCleared Jan 27, 2006123-day reviewClass I21 CFR 862.1680Recalls 2

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Drg Intl., Inc. · CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone

Cleared on Jan 27, 2006 after a 123-day review. The FDA summary names its predicate without a number. It has been recalled 2 times.

Decided
Jan 27, 2006
Review
123 days
Class
Class I
Product code
CDZ
Recalls
2
Predicates
0

The FDA summary names its predicate without a number.

FIG. 1 — Lineage of K052649Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CDZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CDZ device

  1. #1 K252728 IDS-iSYS Total Testosteronescore 11.8 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—LIA saliva test
Named without a submission number
—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Jul 5, 2024Class IIIZ-2622-2024Nonconforming Material/ComponentInvalid Controls. The Low Control is out of range; too high which causes invalid runs that would result in repeating the runs and delays for reporting results to patients.
May 21, 2019Class IIZ-2159-2019Under Investigation by firmSalivary assay may observe a higher percentage of samples with 0 pg/ml testosterone or results which are too low. Saliva samples in the low measuring range of the kit(< 50 pg/ml) were assayed significantly lower

No ancestor or descendant has a Class I recall.

How does its category compare?

All CDZ devices

CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · CDZ

2in 2024

2007: 12009: 12010: 22011: 22012: 12013: 12014: 12015: 22016: 42018: 12019: 42020: 12022: 12023: 12024: 22026 (partial year): 1
2007high 4 (2016) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CDZ

141in 2019

2016: 276 days median2019: 141 days median
2007high 276 (2016) · low 141 (2019)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CDZ

1in 2025

2010: 12013: 12018: 12022: 12024: 12025: 12026 (partial year): 1
2007high 1 (2010) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · CDZ

17in 2025

2007: 62008: 32009: 12010: 12011: 192012: 92013: 72014: 102015: 72016: 52017: 122018: 52019: 32020: 122021: 72022: 32023: 102024: 112025: 17
2007high 19 (2011) · low 1 (2009)2025

MAUDE reports naming product code CDZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—06
20080—03
20091—01
20102—11
20112—019
20121—09
20131—17
20141—010
20152—07
2016427605
20170—012
20181—15
2019414103
20201—012
20210—07
20221—13
20231—010
20242—111
20250—117
20261—1—

What is it indicated for?

An enzyme immunoassay for the in vitro diagnostic quantitative measurement of free active testosterone in saliva.

Measurement of testosterone is used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in females hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K052649: DRG SLV Testosterone Elisa Test.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K052649

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026